Medifocus Inc. Announces Extension of Convertible Debenture Financing

Medifocus Inc. (TSX VENTURE:MFS)(OTCQX:MDFZF) announced today a further
extension of the final closing of its non-brokered private placement (the
Offering) of $6,000,000 previously announced in August 2013. The Company
previously disclosed the completion of the first tranche of the Offering, in an
amount of $3,540,000, on December 18, 2013 and now expects to complete the
Offering by February 28, 2014. All other terms and conditions of the Offering
remain unchanged. 


About Medifocus

Medifocus owns two fully developed technology platforms with comprehensive
United States and international patent protection: (i) The Endo-thermotherapy
Platform-a catheter-basis focused heat technology platform that utilizes natural
body openings to deliver precise microwave thermotherapy to the diseased sites.
The United States Food and Drugs Administration (FDA) approved Prolieve
Thermodilatation System for the treatment of Benign Prostatic Hyperplasia (BPH)
was developed based on the Endo-thermotherapy and is currently generating
revenue; and (ii) the Adaptive Phased Array (APA) Microwave Focusing Platform,
invented by the Massachusetts Institute of Technology, licensed to Medifocus
directs precisely focused microwave energy at tumor center to induce shrinkage
or eradication of tumors without undue harm to surrounding tissue. Medifocus'
APA 1000 Breast Cancer Treatment System, developed from the APA technology
platform, has received approval from the FDA and Health Canada to conduct the
pivotal Phase III clinical trials. Medifocus believes that these two technology
platforms can provide the design basis for the development of multiple cancer
treatment systems for surface, subsurface and deep seated localized and regional
cancers. Please visit www.medifocusinc.com, www.prolieve.com and
http://www.facebook.com/pages/Medifocus-Inc-Company-Page/546315028715627 for
more details.


Forward-Looking Statements and Information

This news release contains "forward-looking statements" and "forward-looking
information", which may not be based on historical facts. Forward-looking
statements and forward-looking information, include, but are not limited to,
information and statements with respect the structure and the proceeds of the
Offering and the expected use of the proceeds. Forward-looking statements are
frequently characterized by words such as "plan," "expect," "project," "intend,"
"believe," "anticipate", "estimate" and other similar words, or statements that
certain events or conditions "may" or "will" occur. Forward-looking statements
are based on the opinions and estimates of management at the date the statements
are made. Such forward-looking statements and forward-looking information
involve known and unknown risks, uncertainties and other factors that may cause
the actual results events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements or forward-looking information. These factors should
be considered carefully and readers are cautioned not to place undue reliance on
such forward-looking statements and forward-looking information. Except as
required by applicable securities laws, Medifocus disclaims any obligation to
update any such factors or to publicly announce the results of any revisions to
any of the forward-looking statements or forward-looking information contained
herein to reflect future results, events or developments.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Medifocus Contact:
Medifocus, Inc.
John Mon
COO
410-290-5734
[e-mail]


Investor Relations Contact:
Consulting for Strategic Growth 1
Robert Giordano
917-327-3938
[e-mail]